Stem definition | Drug id | CAS RN |
---|---|---|
calcium channel blockers, nifedipine derivatives | 1922 | 21829-25-4 |
Dose | Unit | Route |
---|---|---|
30 | mg | O |
30 | mg | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.01 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.71 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.79 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 7.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.04 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.90 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 31, 1981 | FDA | PFIZER |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Exposure during pregnancy | 647.01 | 41.08 | 196 | 1728 | 25023 | 2331138 |
Drug hypersensitivity | 569.97 | 41.08 | 207 | 1717 | 46436 | 2309725 |
Premature delivery | 540.37 | 41.08 | 113 | 1811 | 3087 | 2353074 |
Maternal exposure during pregnancy | 527.46 | 41.08 | 149 | 1775 | 14714 | 2341447 |
Completed suicide | 405.67 | 41.08 | 132 | 1792 | 20902 | 2335259 |
Premature baby | 387.12 | 41.08 | 86 | 1838 | 3118 | 2353043 |
Hypotension | 375.50 | 41.08 | 139 | 1785 | 32297 | 2323864 |
Toxicity to various agents | 333.92 | 41.08 | 128 | 1796 | 32626 | 2323535 |
Low birth weight baby | 258.66 | 41.08 | 49 | 1875 | 780 | 2355381 |
Foetal exposure during pregnancy | 256.49 | 41.08 | 68 | 1856 | 5184 | 2350977 |
Drug ineffective | 203.72 | 41.08 | 131 | 1793 | 101493 | 2254668 |
Caesarean section | 199.87 | 41.08 | 53 | 1871 | 4028 | 2352133 |
Hypertension | 198.55 | 41.08 | 84 | 1840 | 27277 | 2328884 |
Blood pressure inadequately controlled | 175.89 | 41.08 | 36 | 1888 | 864 | 2355297 |
Bradycardia | 164.84 | 41.08 | 56 | 1868 | 9925 | 2346236 |
Blood pressure increased | 163.65 | 41.08 | 64 | 1860 | 16922 | 2339239 |
Pre-eclampsia | 162.87 | 41.08 | 37 | 1887 | 1467 | 2354694 |
Premature labour | 135.39 | 41.08 | 34 | 1890 | 2072 | 2354089 |
Oedema peripheral | 120.85 | 41.08 | 57 | 1867 | 23706 | 2332455 |
Medication error | 115.40 | 41.08 | 38 | 1886 | 6093 | 2350068 |
Acute pulmonary oedema | 109.76 | 41.08 | 26 | 1898 | 1237 | 2354924 |
Foetal growth restriction | 107.11 | 41.08 | 25 | 1899 | 1115 | 2355046 |
Pulmonary oedema | 97.16 | 41.08 | 35 | 1889 | 7328 | 2348833 |
Acute kidney injury | 94.55 | 41.08 | 51 | 1873 | 28071 | 2328090 |
Drug interaction | 92.81 | 41.08 | 51 | 1873 | 29112 | 2327049 |
Dizziness | 91.18 | 41.08 | 65 | 1859 | 58600 | 2297561 |
Metabolic acidosis | 88.56 | 41.08 | 31 | 1893 | 5967 | 2350194 |
Headache | 87.63 | 41.08 | 72 | 1852 | 80107 | 2276054 |
Foetal death | 84.81 | 41.08 | 23 | 1901 | 1889 | 2354272 |
Off label use | 84.41 | 41.08 | 68 | 1856 | 73530 | 2282631 |
Shock | 84.15 | 41.08 | 27 | 1897 | 3977 | 2352184 |
Overdose | 83.77 | 41.08 | 42 | 1882 | 19865 | 2336296 |
Tachycardia | 79.12 | 41.08 | 38 | 1886 | 16371 | 2339790 |
Cardiac arrest | 76.33 | 41.08 | 36 | 1888 | 14894 | 2341267 |
Product complaint | 72.95 | 41.08 | 25 | 1899 | 4513 | 2351648 |
Neonatal respiratory distress syndrome | 72.50 | 41.08 | 16 | 1908 | 552 | 2355609 |
Blood pressure decreased | 72.15 | 41.08 | 30 | 1894 | 9206 | 2346955 |
Porphyria acute | 70.57 | 41.08 | 12 | 1912 | 98 | 2356063 |
Hypoxia | 68.83 | 41.08 | 26 | 1898 | 6201 | 2349960 |
Palpitations | 64.17 | 41.08 | 33 | 1891 | 16423 | 2339738 |
Renal impairment | 63.07 | 41.08 | 28 | 1896 | 10064 | 2346097 |
Respiratory arrest | 61.84 | 41.08 | 24 | 1900 | 6154 | 2350007 |
Intentional overdose | 59.99 | 41.08 | 28 | 1896 | 11293 | 2344868 |
Hypoglycaemia | 57.96 | 41.08 | 25 | 1899 | 8382 | 2347779 |
Haemolysis | 57.72 | 41.08 | 15 | 1909 | 1043 | 2355118 |
Product use in unapproved indication | 57.18 | 41.08 | 27 | 1897 | 11173 | 2344988 |
Multiple organ dysfunction syndrome | 56.90 | 41.08 | 24 | 1900 | 7617 | 2348544 |
Product residue present | 51.93 | 41.08 | 14 | 1910 | 1122 | 2355039 |
Dyspnoea | 51.19 | 41.08 | 53 | 1871 | 78680 | 2277481 |
Suicide attempt | 50.93 | 41.08 | 25 | 1899 | 11257 | 2344904 |
Proteinuria | 50.90 | 41.08 | 17 | 1907 | 2833 | 2353328 |
CD30 expression | 50.45 | 41.08 | 7 | 1917 | 10 | 2356151 |
Drug intolerance | 49.13 | 41.08 | 26 | 1898 | 13691 | 2342470 |
Stillbirth | 48.63 | 41.08 | 14 | 1910 | 1427 | 2354734 |
Live birth | 45.61 | 41.08 | 13 | 1911 | 1278 | 2354883 |
Cardio-respiratory arrest | 43.47 | 41.08 | 21 | 1903 | 9125 | 2347036 |
HELLP syndrome | 43.00 | 41.08 | 9 | 1915 | 240 | 2355921 |
Heart rate decreased | 42.97 | 41.08 | 16 | 1908 | 3660 | 2352501 |
Death | 42.73 | 41.08 | 49 | 1875 | 81419 | 2274742 |
Pseudolymphoma | 41.54 | 41.08 | 8 | 1916 | 138 | 2356023 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hypotension | 467.07 | 41.29 | 161 | 1078 | 29493 | 1716049 |
Completed suicide | 348.45 | 41.29 | 112 | 1127 | 16200 | 1729342 |
Toxicity to various agents | 313.65 | 41.29 | 120 | 1119 | 29021 | 1716521 |
Foetal exposure during pregnancy | 290.98 | 41.29 | 79 | 1160 | 6280 | 1739262 |
Premature baby | 276.20 | 41.29 | 65 | 1174 | 2877 | 1742665 |
Bradycardia | 264.24 | 41.29 | 82 | 1157 | 10452 | 1735090 |
Shock | 210.17 | 41.29 | 56 | 1183 | 4105 | 1741437 |
Drug hypersensitivity | 208.21 | 41.29 | 75 | 1164 | 15060 | 1730482 |
Low birth weight baby | 203.97 | 41.29 | 41 | 1198 | 846 | 1744696 |
Cardiac arrest | 182.33 | 41.29 | 69 | 1170 | 15861 | 1729681 |
Intentional overdose | 168.05 | 41.29 | 54 | 1185 | 7616 | 1737926 |
Acute kidney injury | 150.64 | 41.29 | 76 | 1163 | 34868 | 1710674 |
Drug interaction | 132.69 | 41.29 | 65 | 1174 | 27893 | 1717649 |
Suicide attempt | 129.57 | 41.29 | 44 | 1195 | 7337 | 1738205 |
Overdose | 120.43 | 41.29 | 52 | 1187 | 16649 | 1728893 |
Bezoar | 120.35 | 41.29 | 20 | 1219 | 131 | 1745411 |
Orthostatic hypotension | 117 | 41.29 | 34 | 1205 | 3397 | 1742145 |
Metabolic acidosis | 113.90 | 41.29 | 37 | 1202 | 5365 | 1740177 |
Gingival hypertrophy | 101.55 | 41.29 | 20 | 1219 | 367 | 1745175 |
Oesophageal obstruction | 91.36 | 41.29 | 15 | 1224 | 90 | 1745452 |
Hypertension | 85.37 | 41.29 | 43 | 1196 | 19405 | 1726137 |
Foetal growth restriction | 79.27 | 41.29 | 18 | 1221 | 666 | 1744876 |
Depressed level of consciousness | 73.01 | 41.29 | 28 | 1211 | 6564 | 1738978 |
Dizziness | 72.33 | 41.29 | 47 | 1192 | 34314 | 1711228 |
Loss of consciousness | 71.45 | 41.29 | 35 | 1204 | 14840 | 1730702 |
Blood pressure increased | 69.25 | 41.29 | 31 | 1208 | 10722 | 1734820 |
Polydactyly | 67.30 | 41.29 | 13 | 1226 | 214 | 1745328 |
Oedema peripheral | 67.03 | 41.29 | 34 | 1205 | 15516 | 1730026 |
Lactic acidosis | 64.80 | 41.29 | 24 | 1215 | 5105 | 1740437 |
Renal failure | 61.66 | 41.29 | 35 | 1204 | 19982 | 1725560 |
Hyperkalaemia | 59.38 | 41.29 | 26 | 1213 | 8521 | 1737021 |
Blood pressure decreased | 58.82 | 41.29 | 25 | 1214 | 7621 | 1737921 |
General physical health deterioration | 57.42 | 41.29 | 29 | 1210 | 13089 | 1732453 |
Acute lung injury | 56.66 | 41.29 | 11 | 1228 | 186 | 1745356 |
Pulmonary oedema | 55.56 | 41.29 | 23 | 1216 | 6563 | 1738979 |
Dyspnoea | 50.79 | 41.29 | 45 | 1194 | 52014 | 1693528 |
Syncope | 46.89 | 41.29 | 26 | 1213 | 14143 | 1731399 |
Left ventricular dysfunction | 45.65 | 41.29 | 13 | 1226 | 1198 | 1744344 |
Blood pressure inadequately controlled | 44.22 | 41.29 | 11 | 1228 | 602 | 1744940 |
Oesophageal haemorrhage | 42.56 | 41.29 | 9 | 1230 | 237 | 1745305 |
Multiple organ dysfunction syndrome | 42.07 | 41.29 | 21 | 1218 | 9221 | 1736321 |
Source | Code | Description |
---|---|---|
ATC | C07FB03 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents and calcium channel blockers |
ATC | C08CA05 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
ATC | C08CA55 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
ATC | C08GA01 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS CALCIUM CHANNEL BLOCKERS AND DIURETICS Calcium channel blockers and diuretics |
FDA MoA | N0000000069 | Calcium Channel Antagonists |
FDA EPC | N0000175421 | Dihydropyridine Calcium Channel Blocker |
FDA CS | M0006414 | Dihydropyridines |
MeSH PA | D002121 | Calcium Channel Blockers |
MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D012102 | Reproductive Control Agents |
CHEBI has role | CHEBI:35620 | vasodilator agent |
CHEBI has role | CHEBI:66993 | tocolytic agent |
MeSH PA | D015149 | Tocolytic Agents |
MeSH PA | D014665 | Vasodilator Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Prinzmetal angina | indication | 87343002 | |
Angina pectoris | indication | 194828000 | |
Premature labor | off-label use | 6383007 | |
Raynaud's phenomenon | off-label use | 266261006 | |
Cirrhosis of liver | contraindication | 19943007 | DOID:5082 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Stenosis of intestine | contraindication | 23065003 | |
Low blood pressure | contraindication | 45007003 | |
Chronic heart failure | contraindication | 48447003 | |
Chronic idiopathic constipation | contraindication | 82934008 | |
Left heart failure | contraindication | 85232009 | |
Cardiogenic shock | contraindication | 89138009 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Gastrointestinal obstruction | contraindication | 126765001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pyloric obstruction | contraindication | 244815007 | |
Peripheral edema | contraindication | 271809000 | |
Continent ileostomy - stoma | contraindication | 311414006 | |
Non-Q wave myocardial infarction | contraindication | 314207007 | |
Acute coronary syndrome | contraindication | 394659003 | |
Porphyria | contraindication | 418470004 | |
Severe Aortic Valve Stenosis | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.5 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | BLOCKER | Kd | 9.40 | CHEMBL | SCIENTIFIC LITERATURE | |||
Voltage-dependent L-type calcium channel subunit alpha-1D | Ion channel | GATING INHIBITOR | IC50 | 7.70 | IUPHAR | CHEMBL | |||
Voltage-dependent L-type calcium channel subunit alpha-1F | Ion channel | GATING INHIBITOR | IC50 | 6 | IUPHAR | ||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.02 | DRUG MATRIX | |||||
Adenosine receptor A1 | GPCR | Ki | 5.35 | DRUG MATRIX | |||||
Cytochrome P450 1A2 | Enzyme | IC50 | 6.52 | DRUG MATRIX | |||||
cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | IC50 | 4.35 | DRUG MATRIX | |||||
Thromboxane-A synthase | Enzyme | IC50 | 4.73 | DRUG MATRIX | |||||
C-C chemokine receptor type 2 | GPCR | Ki | 6.07 | DRUG MATRIX | |||||
Sodium/nucleoside cotransporter 1 | Transporter | Ki | 5.09 | DRUG MATRIX | |||||
Potassium voltage-gated channel subfamily A member 2 | Ion channel | Kd | 4.70 | WOMBAT-PK | |||||
Voltage-dependent T-type calcium channel subunit alpha-1H | Ion channel | Ki | 4.67 | WOMBAT-PK | |||||
Transthyretin | Secreted | IC50 | 5.66 | WOMBAT-PK | |||||
Glycine receptor subunit alpha-1 | Ion channel | IC50 | 5.48 | CHEMBL | |||||
Adenosine receptor A3 | GPCR | Ki | 5.08 | CHEMBL | |||||
Glutathione reductase, mitochondrial | Enzyme | Ki | 4.76 | CHEMBL | |||||
Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 4.43 | CHEMBL | |||||
Potassium voltage-gated channel subfamily A member 5 | Ion channel | IC50 | 5.21 | CHEMBL | |||||
Adenosine receptor A2a | GPCR | Ki | 4.65 | CHEMBL | |||||
Cytochrome P450 3A4 | Enzyme | IC50 | 5.26 | WOMBAT-PK | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 4.30 | WOMBAT-PK | |||||
Glycine receptor subunit alpha-3 | Ion channel | ANTAGONIST | IC50 | 4.50 | IUPHAR | ||||
Glycine receptor subunit beta | Ion channel | ANTAGONIST | IC50 | 5.90 | IUPHAR | ||||
Bile salt export pump | Transporter | IC50 | 4.51 | CHEMBL | |||||
Myosin light chain kinase, smooth muscle | Kinase | IC50 | 5.69 | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1S | Ion channel | INHIBITOR | IC50 | 6.30 | IUPHAR | ||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.49 | PDSP | |||||
Arachidonate 15-lipoxygenase | Enzyme | IC50 | 4.82 | DRUG MATRIX | |||||
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | IC50 | 9 | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | IC50 | 8.59 | CHEMBL | |||||
Adenosine receptor A2a | GPCR | Ki | 4.74 | CHEMBL | |||||
Cholinesterase | Enzyme | Ki | 5.92 | CHEMBL | |||||
Voltage-gated L-type calcium channel | Ion channel | Ki | 8.33 | CHEMBL | |||||
Adenosine receptor A1 | GPCR | Ki | 5.54 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.34 | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1D | Ion channel | Ki | 8.92 | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | Ki | 8.46 | CHEMBL | |||||
Acetylcholinesterase | Enzyme | Ki | 5.40 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 2 | Enzyme | IC50 | 5.82 | CHEMBL | |||||
Bile salt export pump | Unclassified | IC50 | 4.34 | CHEMBL | |||||
Potassium voltage-gated channel subfamily A member 1 | Unclassified | BLOCKER | IC50 | 4 | IUPHAR | ||||
Potassium voltage-gated channel subfamily A member 2 | Unclassified | BLOCKER | Kd | 4.70 | IUPHAR | ||||
Potassium voltage-gated channel subfamily A member 7 | Unclassified | BLOCKER | IC50 | 4.90 | IUPHAR |
ID | Source |
---|---|
4018390 | VUID |
N0000146717 | NUI |
C0028066 | UMLSCUI |
D00437 | KEGG_DRUG |
017700 | NDDF |
85272000 | SNOMEDCT_US |
4018390 | VANDF |
2302 | MMSL |
7417 | RXNORM |
387490003 | SNOMEDCT_US |
5175 | MMSL |
d00051 | MMSL |
000710 | NDDF |
CHEMBL193 | ChEMBL_ID |
DB01115 | DRUGBANK_ID |
I9ZF7L6G2L | UNII |
3222 | INN_ID |
CHEBI:7565 | CHEBI |
D009543 | MESH_DESCRIPTOR_UI |
4485 | PUBCHEM_CID |
2514 | IUPHAR_LIGAND_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Procardia | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-2600 | CAPSULE | 10 mg | ORAL | NDA | 12 sections |
Procardia | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-2650 | TABLET, FILM COATED, EXTENDED RELEASE | 30 mg | ORAL | NDA | 12 sections |
Procardia | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-2660 | TABLET, FILM COATED, EXTENDED RELEASE | 60 mg | ORAL | NDA | 12 sections |
Procardia | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-2670 | TABLET, FILM COATED, EXTENDED RELEASE | 90 mg | ORAL | NDA | 12 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0228-2497 | CAPSULE, LIQUID FILLED | 10 mg | ORAL | ANDA | 12 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0228-2530 | CAPSULE, LIQUID FILLED | 20 mg | ORAL | ANDA | 12 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0353 | TABLET, FILM COATED, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 11 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0360 | TABLET, FILM COATED, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 11 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0390 | TABLET, FILM COATED, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 11 sections |
NIFEDIPINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-319 | CAPSULE, LIQUID FILLED | 10 mg | ORAL | ANDA | 11 sections |
NIFEDIPINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-948 | TABLET, FILM COATED, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 11 sections |
nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-807 | TABLET, FILM COATED, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 13 sections |
nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-908 | TABLET, FILM COATED, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 12 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-909 | TABLET, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 12 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-194 | CAPSULE | 10 mg | ORAL | ANDA | 11 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-195 | CAPSULE | 20 mg | ORAL | ANDA | 11 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-009 | TABLET, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 11 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-010 | TABLET, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 11 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-011 | TABLET, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 11 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-840 | TABLET, FILM COATED, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 12 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-095 | TABLET, FILM COATED, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 12 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-209 | TABLET, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 17 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-750 | TABLET, FILM COATED, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 12 sections |
Afeditab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-782 | TABLET, FILM COATED, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 12 sections |
Afeditab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-792 | TABLET, FILM COATED, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 12 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-836 | TABLET, FILM COATED, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 12 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-929 | TABLET, FILM COATED, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 12 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43386-440 | CAPSULE | 10 mg | ORAL | ANDA | 10 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45963-152 | TABLET, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 13 sections |
Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0695 | TABLET, FILM COATED, EXTENDED RELEASE | 30 mg | ORAL | NDA authorized generic | 11 sections |